John Maraganore

John Maraganore
Name	John Maraganore
Birth date	1963
Occupation	Biotech executive, scientist
Years active	1985–present
Known for	Leadership at Alnylam Pharmaceuticals

John Maraganore is an American scientist and biotechnology executive notable for leading Alnylam Pharmaceuticals through its transition from a research-stage company to a commercial enterprise in the field of RNA interference therapeutics. He has been involved in translational research, corporate strategy, and ecosystem building across the biotechnology industry, engaging with academic institutions, pharmaceutical companies, investors, and regulatory bodies. His career spans roles at technology startups, multinational corporations, and boardrooms where he has influenced drug development, business development, and policy discussions related to novel modalities.

Early life and education

Maraganore was born in the early 1960s and raised in the United States, where he pursued undergraduate studies that combined interests in chemistry and life sciences. He earned a Bachelor of Science degree before undertaking graduate training that led to a PhD in molecular biology and biochemistry. His doctoral work was connected with research environments associated with Massachusetts Institute of Technology, Harvard University, and research institutes in the northeastern United States. During his formative years he trained alongside investigators from institutions such as Broad Institute, Dana–Farber Cancer Institute, and engaged with centers focusing on nucleic acids and enzymology, which laid a foundation for subsequent work in therapeutic modalities and translational medicine.

Scientific and research career

Maraganore began his scientific career in research and discovery roles, contributing to projects that intersected with pharmaceutical development and biotechnology innovation. Early positions placed him in laboratories affiliated with companies and collaborations involving Merck & Co., Novartis, and biotechnology startups in the Boston and San Francisco clusters. His scientific interests encompassed nucleic acid chemistry, RNA biology, and delivery technologies—areas that connected to research advances at Cold Spring Harbor Laboratory, RNA Society, and groups studying RNA interference following discoveries by researchers such as Andrew Fire and Craig Mello. Over the course of his research career he worked alongside teams involving investigators from Stanford University, University of California, San Francisco, and industry scientists experienced with monoclonal antibodies, small molecules, and oligonucleotide therapeutics.

Leadership at Alnylam Pharmaceuticals

As chief executive officer of Alnylam Pharmaceuticals, Maraganore guided the company through strategic alliances, clinical development, regulatory interactions, and commercialization efforts centered on RNA interference (RNAi) therapies. Under his leadership Alnylam executed collaborations with legacy pharmaceutical firms including Roche, Novartis and Sanofi, and advanced programs for conditions that intersected with specialists at referral centers such as Mayo Clinic, Massachusetts General Hospital, and Johns Hopkins Hospital. He oversaw pivotal clinical programs that pursued indications evaluated by regulatory agencies like the U.S. Food and Drug Administration and the European Medicines Agency, and navigated challenges common to biotech companies working on novel modalities, engaging with investors on NASDAQ and interacting with venture capital firms and strategic partners in the biotech finance ecosystem. Maraganore also emphasized manufacturing scale-up, quality systems aligned with Good Manufacturing Practice expectations, and global market access strategies involving payers and health technology assessment bodies such as National Institute for Health and Care Excellence.

Board memberships and advisory roles

Beyond his executive role, Maraganore has served on corporate boards and advisory committees spanning start-ups, midsize biotech companies, and non-profit research entities. He has been involved with governance at organizations collaborating with academic consortia like The Rockefeller University, Cold Spring Harbor Laboratory, and translational networks such as Cystic Fibrosis Foundation-linked programs. His advisory roles extended to investor groups, biotech incubators, and consortia that include members from Biotechnology Innovation Organization and regional life-science economic development initiatives in locales such as Cambridge, Massachusetts and San Francisco Bay Area. He has also engaged with policy forums where stakeholders include representatives from National Institutes of Health and global public–private partnership platforms focused on accelerating therapeutic innovation.

Awards, honors, and recognition

Maraganore’s leadership and contributions to biotechnology have been recognized by industry organizations, academic societies, and trade publications. Honors have highlighted his role in developing RNAi therapeutics amid recognition from peer groups tied to translational science, corporate leadership awards conferred within the biotechnology sector, and listings by business media outlets focused on healthcare innovation and entrepreneurship. He has participated as a speaker and panelist at conferences organized by entities such as American Society of Clinical Oncology, BIO International Convention, and meetings convened by the RNA Society, reflecting acknowledgement by both scientific and commercial communities.

Personal life and philanthropy

In his personal life Maraganore has supported philanthropic causes related to scientific research, education, and community health, partnering with charities and foundations that work with academic medical centers and patient advocacy groups including organizations focused on rare diseases and neurodegenerative disorders. He has been involved with initiatives that foster workforce development in biotechnology in regions with concentrations of life-science companies, and he has supported outreach programs connecting university research programs at institutions like Harvard Medical School and MIT with entrepreneurial and mentorship networks. Maraganore resides in the United States and maintains ties with professional and civic organizations in major biotech hubs.

Category:Biotechnology executives Category:American scientists